PURPOSE: To determine the frequency with which elevated plasma transforming growth factor-beta 1 (TGF beta 1) concentrations occur in lung cancer patients, to determine the kinetics of TGF beta 1 expression during and after radiotherapy and to correlate plasma TGF beta 1 levels with disease status after treatment. MATERIALS AND METHODS: Plasma samples were obtained before, during and after radiotherapy in 54 patients with lung cancer and 20 normal controls. Plasma TGF beta 1 levels were measured using an enzyme-linked immunosorbent assay. RESULTS: Baseline TGF beta 1 levels in lung cancer patients and normal controls were 13.0 +/- 2.5 and 4.4 +/- 0.3 ng/ml, respectively. Elevated TGF beta 1 were found in 50% (27/54) of lung cancer patients. During radiation therapy plasma TGF beta 1 levels declined, however, by the completion of treatment the mean TGF beta 1 level had not normalized in patients with lung cancer. The TGF beta 1 level at last follow-up correlated with disease status in those patients with an increased pretreatment plasma level. Three of four patients with no evidence of cancer had normal follow-up TGF beta 1 levels, compared to 2/16 patients with residual or recurrent tumor (P = 0.02). CONCLUSIONS: Elevated plasma TGF beta 1 levels occur frequently in patients with lung cancer. In those patients with an elevated plasma TGF beta 1 level at diagnosis, monitoring this level may be useful in detecting both disease persistence and recurrence after therapy.
PURPOSE: To determine the frequency with which elevated plasma transforming growth factor-beta 1 (TGF beta 1) concentrations occur in lung cancerpatients, to determine the kinetics of TGF beta 1 expression during and after radiotherapy and to correlate plasma TGF beta 1 levels with disease status after treatment. MATERIALS AND METHODS: Plasma samples were obtained before, during and after radiotherapy in 54 patients with lung cancer and 20 normal controls. Plasma TGF beta 1 levels were measured using an enzyme-linked immunosorbent assay. RESULTS: Baseline TGF beta 1 levels in lung cancerpatients and normal controls were 13.0 +/- 2.5 and 4.4 +/- 0.3 ng/ml, respectively. Elevated TGF beta 1 were found in 50% (27/54) of lung cancerpatients. During radiation therapy plasma TGF beta 1 levels declined, however, by the completion of treatment the mean TGF beta 1 level had not normalized in patients with lung cancer. The TGF beta 1 level at last follow-up correlated with disease status in those patients with an increased pretreatment plasma level. Three of four patients with no evidence of cancer had normal follow-up TGF beta 1 levels, compared to 2/16 patients with residual or recurrent tumor (P = 0.02). CONCLUSIONS: Elevated plasma TGF beta 1 levels occur frequently in patients with lung cancer. In those patients with an elevated plasma TGF beta 1 level at diagnosis, monitoring this level may be useful in detecting both disease persistence and recurrence after therapy.
Authors: Hyo-Sung Jeon; Tatiana Dracheva; Sei-Hoon Yang; Daoud Meerzaman; Junya Fukuoka; Abbas Shakoori; Konstantin Shilo; William D Travis; Jin Jen Journal: Cancer Res Date: 2008-12-01 Impact factor: 12.701
Authors: Felicita Baratelli; Jay M Lee; Saswati Hazra; Ying Lin; Tonya C Walser; Dorthe Schaue; Peter S Pak; David Elashoff; Karen Reckamp; Ling Zhang; Michael C Fishbein; Sherven Sharma; Steven M Dubinett Journal: Am J Transl Res Date: 2010-06-30 Impact factor: 4.060
Authors: Dirk De Ruysscher; Jianyue Jin; Tim Lautenschlaeger; Jin-Xiong She; Zhongxing Liao; Feng-Ming Spring Kong Journal: Transl Lung Cancer Res Date: 2017-12
Authors: Tiva T VanCleave; Jason H Moore; Marnita L Benford; Guy N Brock; Ted Kalbfleisch; Richard N Baumgartner; James W Lillard; Rick A Kittles; La Creis R Kidd Journal: Prostate Date: 2010-03-01 Impact factor: 4.104